Related Experiment Video
Updated: Apr 30, 2026
09:03
Forward Genetic Approaches in Chlamydia trachomatis
Published on: October 23, 2013
12.4K
Recent advances in technologies for developing drugs against Chlamydia pneumoniae
1Division of Pharmaceutical Biosciences, CDR, Faculty of Pharmacy, University of Helsinki , FI-00014 Helsinki , Finland +358 9 19159164 ; leena.hanski@helsinki.fi.
Expert Opinion on Drug Discovery
|May 6, 2014
Summary
Researchers are exploring novel drug discovery strategies for Chlamydia pneumoniae, focusing on new agents and therapeutic targets. Advances in genomics and genetic manipulation offer promising avenues for developing effective treatments against this bacterium.
Area of Science:
- Microbiology
- Infectious Diseases
- Drug Discovery
Background:
- Chlamydia pneumoniae is known for unique morphology, host cell manipulation, and links to chronic inflammatory diseases.
- Its complex biology has long fascinated researchers and medical professionals.
Purpose of the Study:
- To review current drug discovery and development efforts against Chlamydia pneumoniae.
- To highlight recent advances in genomics, proteomics, and genetic technologies relevant to C. pneumoniae.
Main Methods:
- Review of non-conventional antichlamydial agents.
- Exploration of targeting the chlamydial type 3 secretion system.
- Analysis of approved drug repositioning and combination therapies.
- Discussion of recent genomics, proteomics, and genetic manipulation research.
Main Results:
- Several strategies are being investigated for C. pneumoniae drug development, including novel agents and targeting specific bacterial systems.
- Advances in understanding C. pneumoniae biology and genetics are providing new insights.
- Drug repositioning and combination therapies show potential.
Conclusions:
- Future research should prioritize phenotypic assays for persistent infections and evaluate candidate drug properties.
- Development of narrow-spectrum antibacterial agents is crucial for successful lead generation.
- Integrating advances in C. pneumoniae biology and genetic transformation will enhance therapeutic target identification.
Keywords:
Chlamydia pneumoniaeGram-negativeatypical pneumoniabacteriumdrug discoverypersistencerespiratory pathogenMore Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
17.4K
10:35Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis
Published on: January 30, 2020
6.4K
Related Concept Videos
01:29Bacterial Phylum Chlamydiae
842
The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic...
842
01:25Mechanism of Antibiotic Resistance in MRSA
219
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
219
01:29Microorganisms in Medicine and Therapeutics
1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
01:14Atypical Pneumonia
84
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
84
01:27Combined Effects of Drugs: Synergism
6.2K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.2K
01:25Clinical Significance of Antibiotic Resistance
90
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
90